Latest News

Pivotal FDA approvals in breast cancer treatment focus on precision medicine and innovative therapies in 2025.

Pharmacists enhance oncology care by guiding younger patients through precision diagnostics like ctDNA MRD testing, driving innovation in cancer treatment.

The FDA has approved a new combination therapy for BRCA2-mutated metastatic prostate cancer, showing significant efficacy in clinical trials.

Exploratory findings from the MONALEESA-3 trial presented at SABCS 2025 show ribociclib plus fulvestrant significantly enhances survival in ILC.

Discover how antibody drug conjugates (ADCs) are transforming treatment for HER2-positive breast cancer with brain metastases at SABCS 2025.

Kelly Gable, professor and director of well-being and resilience at Southern Illinois University Edwardsville School of Pharmacy, discusses her own cancer journey and how pharmacists need to be more involved and proactive in patients' mental health.

Effective Nutrition Strategies for Diabetes Management Focus on Personalized Dietary Approaches to Enhance Glycemic Control and Overall Health

After 2 initial doses, inebilizumab is administered with only 2 doses a year.

A study reveals that many asthma patients switch biologics due to perceived ineffectiveness, highlighting the need for personalized treatment strategies.

Aflibercept biosimilar QL1207 shows comparable efficacy to the reference drug in treating diabetic macular edema, offering a potentially affordable treatment option for those facing adherence and accessibility issues.

Experts explore the evolving role of HER2- and TROP2-targeted therapies in breast cancer treatment at SABCS 2025, highlighting ADC advancements.

FDA approves gepotidacin as a new oral treatment for uncomplicated gonorrhea, expanding options against resistant sexually transmitted infections.

Policy Needs to Catch Up to the People Behind the Counter

Latest findings presented at SABCS 2025 support trastuzumab deruxtecan's effectiveness and safety in treating HER2-positive breast cancer.

The FDA approves Flow's at-home depression treatment headset, offering a new approach to managing mental health with transcranial stimulation technology.

New research highlights the benefits of adding isatuximab to standard therapy for newly diagnosed multiple myeloma (NDMM), improving patient outcomes and quality of life.

Tucatinib enhances first-line maintenance therapy for HER2-positive metastatic breast cancer, improving progression-free survival and safety outcomes, as shown in the HER2CLIMB-05 trial.

Cell-cycle–focused CDK inhibitors offer new options for HR+/HER2– metastatic breast cancer after CDK4/6 resistance.

New findings highlight the need for pneumococcal booster vaccinations in children with sickle cell disease to maintain immunity and prevent serious complications.

Asundexian shows promise in reducing ischemic stroke risk without increasing major bleeding, offering hope for secondary stroke prevention.

The FDA approved etuvetidigene autotemcel, the first gene therapy for Wiskott-Aldrich syndrome, transforming treatment options for affected patients.